Search

Your search keyword '"Kim, Sung-Bae"' showing total 87 results
Start Over Author "Kim, Sung-Bae" Publisher american association for cancer research (aacr)
87 results on '"Kim, Sung-Bae"'

1. Data from Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

Author

Tan, Tira J., primary, Sammons, Sarah, primary, Im, Young-Hyuck, primary, She, Lilin, primary, Mundy, Kelly, primary, Bigelow, Robert, primary, Traina, Tiffany A., primary, Anders, Carey, primary, Yeong, Joe, primary, Renzulli, Ezequiel, primary, Kim, Sung-Bae, primary, and Dent, Rebecca, primary

Published
2024
Full Text
View/download PDF

2. Data from Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

Author

Tan, Tira J., primary, Sammons, Sarah, primary, Im, Young-Hyuck, primary, She, Lilin, primary, Mundy, Kelly, primary, Bigelow, Robert, primary, Traina, Tiffany A., primary, Anders, Carey, primary, Yeong, Joe, primary, Renzulli, Ezequiel, primary, Kim, Sung-Bae, primary, and Dent, Rebecca, primary

Published
2024
Full Text
View/download PDF

3. Supplementary Data 1 from Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

Author

Tan, Tira J., primary, Sammons, Sarah, primary, Im, Young-Hyuck, primary, She, Lilin, primary, Mundy, Kelly, primary, Bigelow, Robert, primary, Traina, Tiffany A., primary, Anders, Carey, primary, Yeong, Joe, primary, Renzulli, Ezequiel, primary, Kim, Sung-Bae, primary, and Dent, Rebecca, primary

Published
2024
Full Text
View/download PDF

4. Supplementary Data 1 from Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

Author

Tan, Tira J., primary, Sammons, Sarah, primary, Im, Young-Hyuck, primary, She, Lilin, primary, Mundy, Kelly, primary, Bigelow, Robert, primary, Traina, Tiffany A., primary, Anders, Carey, primary, Yeong, Joe, primary, Renzulli, Ezequiel, primary, Kim, Sung-Bae, primary, and Dent, Rebecca, primary

Published
2024
Full Text
View/download PDF

5. Data from First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Author

Schmid, Peter, primary, Turner, Nicholas C., primary, Barrios, Carlos H., primary, Isakoff, Steven J., primary, Kim, Sung-Bae, primary, Sablin, Marie-Paule, primary, Saji, Shigehira, primary, Savas, Peter, primary, Vidal, Gregory A., primary, Oliveira, Mafalda, primary, O'Shaughnessy, Joyce, primary, Italiano, Antoine, primary, Espinosa, Enrique, primary, Boni, Valentina, primary, White, Shane, primary, Rojas, Beatriz, primary, Freitas-Junior, Ruffo, primary, Chae, Yeesoo, primary, Bondarenko, Igor, primary, Lee, Jieun, primary, Torres Mattos, Cesar, primary, Martinez Rodriguez, Jorge Luis, primary, Lam, Lisa H., primary, Jones, Surai, primary, Reilly, Sarah-Jayne, primary, Huang, Xiayu, primary, Shah, Kalpit, primary, and Dent, Rebecca, primary

Published
2024
Full Text
View/download PDF

6. Supplementary Tables and Figures 1 from First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Author

Schmid, Peter, primary, Turner, Nicholas C., primary, Barrios, Carlos H., primary, Isakoff, Steven J., primary, Kim, Sung-Bae, primary, Sablin, Marie-Paule, primary, Saji, Shigehira, primary, Savas, Peter, primary, Vidal, Gregory A., primary, Oliveira, Mafalda, primary, O'Shaughnessy, Joyce, primary, Italiano, Antoine, primary, Espinosa, Enrique, primary, Boni, Valentina, primary, White, Shane, primary, Rojas, Beatriz, primary, Freitas-Junior, Ruffo, primary, Chae, Yeesoo, primary, Bondarenko, Igor, primary, Lee, Jieun, primary, Torres Mattos, Cesar, primary, Martinez Rodriguez, Jorge Luis, primary, Lam, Lisa H., primary, Jones, Surai, primary, Reilly, Sarah-Jayne, primary, Huang, Xiayu, primary, Shah, Kalpit, primary, and Dent, Rebecca, primary

Published
2024
Full Text
View/download PDF

7. Data from First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Author

Schmid, Peter, primary, Turner, Nicholas C., primary, Barrios, Carlos H., primary, Isakoff, Steven J., primary, Kim, Sung-Bae, primary, Sablin, Marie-Paule, primary, Saji, Shigehira, primary, Savas, Peter, primary, Vidal, Gregory A., primary, Oliveira, Mafalda, primary, O'Shaughnessy, Joyce, primary, Italiano, Antoine, primary, Espinosa, Enrique, primary, Boni, Valentina, primary, White, Shane, primary, Rojas, Beatriz, primary, Freitas-Junior, Ruffo, primary, Chae, Yeesoo, primary, Bondarenko, Igor, primary, Lee, Jieun, primary, Torres Mattos, Cesar, primary, Martinez Rodriguez, Jorge Luis, primary, Lam, Lisa H., primary, Jones, Surai, primary, Reilly, Sarah-Jayne, primary, Huang, Xiayu, primary, Shah, Kalpit, primary, and Dent, Rebecca, primary

Published
2024
Full Text
View/download PDF

8. Supplementary Tables and Figures 1 from First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Author

Schmid, Peter, primary, Turner, Nicholas C., primary, Barrios, Carlos H., primary, Isakoff, Steven J., primary, Kim, Sung-Bae, primary, Sablin, Marie-Paule, primary, Saji, Shigehira, primary, Savas, Peter, primary, Vidal, Gregory A., primary, Oliveira, Mafalda, primary, O'Shaughnessy, Joyce, primary, Italiano, Antoine, primary, Espinosa, Enrique, primary, Boni, Valentina, primary, White, Shane, primary, Rojas, Beatriz, primary, Freitas-Junior, Ruffo, primary, Chae, Yeesoo, primary, Bondarenko, Igor, primary, Lee, Jieun, primary, Torres Mattos, Cesar, primary, Martinez Rodriguez, Jorge Luis, primary, Lam, Lisa H., primary, Jones, Surai, primary, Reilly, Sarah-Jayne, primary, Huang, Xiayu, primary, Shah, Kalpit, primary, and Dent, Rebecca, primary

Published
2024
Full Text
View/download PDF

9. Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

Author

Tan, Tira J., primary, Sammons, Sarah, additional, Im, Young-Hyuck, additional, She, Lilin, additional, Mundy, Kelly, additional, Bigelow, Robert, additional, Traina, Tiffany A., additional, Anders, Carey, additional, Yeong, Joe, additional, Renzulli, Ezequiel, additional, Kim, Sung-Bae, additional, and Dent, Rebecca, additional

Published
2024
Full Text
View/download PDF

10. Data from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

Author

Cescon, David W., primary, Hilton, John, primary, Morales Murilo, Serafin, primary, Layman, Rachel M., primary, Pluard, Timothy, primary, Yeo, Belinda, primary, Park, In Hae, primary, Provencher, Louise, primary, Kim, Sung-Bae, primary, Im, Young-Hyuck, primary, Wyce, Anastasia, primary, Krishnatry, Anu Shilpa, primary, Hicks, Kirsty, primary, Zhang, Qu, primary, Barbash, Olena, primary, Khaled, Ahmed, primary, Horner, Thierry, primary, Dhar, Arindam, primary, Oliveira, Mafalda, primary, and Sparano, Joseph A., primary

Published
2024
Full Text
View/download PDF

11. Data from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

Author

Cescon, David W., primary, Hilton, John, primary, Morales Murilo, Serafin, primary, Layman, Rachel M., primary, Pluard, Timothy, primary, Yeo, Belinda, primary, Park, In Hae, primary, Provencher, Louise, primary, Kim, Sung-Bae, primary, Im, Young-Hyuck, primary, Wyce, Anastasia, primary, Krishnatry, Anu Shilpa, primary, Hicks, Kirsty, primary, Zhang, Qu, primary, Barbash, Olena, primary, Khaled, Ahmed, primary, Horner, Thierry, primary, Dhar, Arindam, primary, Oliveira, Mafalda, primary, and Sparano, Joseph A., primary

Published
2024
Full Text
View/download PDF

12. Supplementary Data1 from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

Author

Cescon, David W., primary, Hilton, John, primary, Morales Murilo, Serafin, primary, Layman, Rachel M., primary, Pluard, Timothy, primary, Yeo, Belinda, primary, Park, In Hae, primary, Provencher, Louise, primary, Kim, Sung-Bae, primary, Im, Young-Hyuck, primary, Wyce, Anastasia, primary, Krishnatry, Anu Shilpa, primary, Hicks, Kirsty, primary, Zhang, Qu, primary, Barbash, Olena, primary, Khaled, Ahmed, primary, Horner, Thierry, primary, Dhar, Arindam, primary, Oliveira, Mafalda, primary, and Sparano, Joseph A., primary

Published
2024
Full Text
View/download PDF

13. Supplementary Data1 from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

Author

Cescon, David W., primary, Hilton, John, primary, Morales Murilo, Serafin, primary, Layman, Rachel M., primary, Pluard, Timothy, primary, Yeo, Belinda, primary, Park, In Hae, primary, Provencher, Louise, primary, Kim, Sung-Bae, primary, Im, Young-Hyuck, primary, Wyce, Anastasia, primary, Krishnatry, Anu Shilpa, primary, Hicks, Kirsty, primary, Zhang, Qu, primary, Barbash, Olena, primary, Khaled, Ahmed, primary, Horner, Thierry, primary, Dhar, Arindam, primary, Oliveira, Mafalda, primary, and Sparano, Joseph A., primary

Published
2024
Full Text
View/download PDF

14. First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Author

Schmid, Peter, primary, Turner, Nicholas C., additional, Barrios, Carlos H., additional, Isakoff, Steven Jay., additional, Kim, Sung-Bae, additional, Sablin, Marie-Paule, additional, Saji, Shigehira, additional, Savas, Peter, additional, Vidal, Gregory A., additional, Oliveira, Mafalda, additional, O’Shaughnessy, Joyce, additional, Italiano, Antoine, additional, Espinosa, Enrique, additional, Boni, Valentina, additional, White, Shane, additional, Rojas, Beatriz, additional, Freitas-Junior, Ruffo, additional, Chae, Yeesoo, additional, Bondarenko, Igor, additional, Lee, Jieun, additional, Torres Mattos, Cesar, additional, Martinez Rodriguez, Jorge Luis., additional, Lam, Lisa, additional, Jones, Surai, additional, Reilly, Sarah-Jayne, additional, Huang, Xiayu, additional, Shah, Kalpit, additional, and Dent, Rebecca, additional

Published
2023
Full Text
View/download PDF

15. A Phase I/II Study of GSK525762 Combined With Fulvestrant in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2−) Advanced or Metastatic Breast Cancer

Author

Cescon, David W., primary, Hilton, John, additional, Morales Murilo, Serafín, additional, Layman, Rachel M., additional, Pluard, Timothy, additional, Yeo, Belinda, additional, Park, In Hae, additional, Provencher, Louise, additional, Kim, Sung-Bae, additional, Im, Young-Hyuck, additional, Wyce, Anastasia, additional, Krishnatry, Anu Shilpa, additional, Hicks, Kirsty, additional, Zhang, Qu, additional, Barbash, Olena, additional, Khaled, Ahmed, additional, Horner, Thierry, additional, Dhar, Arindam, additional, Oliveira, Mafalda, additional, and Sparano, Joseph A., additional

Published
2023
Full Text
View/download PDF

16. Table S1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

17. Figure S4 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

18. Table S3 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Material 1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

20. Figure S4 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

21. Table S2 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

22. Table S4 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Material 1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

24. Table S4 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

25. Data from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

26. Data from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

27. Table S1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

28. Figure S2 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

29. Figure S3 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

30. Figure S2 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

31. Figure S1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

32. Table S2 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

33. Figure S1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

34. Table S3 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

35. Figure S3 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, primary, Muzaffar, Jameel, primary, Keam, Bhumsuk, primary, Bowles, Daniel W., primary, Wong, Deborah J., primary, Ho, Alan L., primary, Kim, Sung-Bae, primary, Worden, Francis, primary, Yun, Tak, primary, Meng, Xianzhang, primary, Van Tornout, Jan M., primary, Conlan, Maureen G., primary, and Kang, Hyunseok, primary

Published
2023
Full Text
View/download PDF

36. Abstract PO-008: Association of plasma Epstein-Barr virus DNA and clinical response in patients with recurrent and/or metastatic nasopharyngeal cancer treated with pembrolizumab or standard-of-care chemotherapy in KEYNOTE-122

Author

Chan, Anthony T. C., primary, Lee, Victor Ho Fun, additional, Hong, Ruey-Long, additional, Ahn, Myung-Ju, additional, Chong, Wan Qin, additional, Spreafico, Anna, additional, Kim, Sung-Bae, additional, Ho, Gwo Fuang, additional, Caguioa, Priscilla B., additional, Ngamphaiboon, Nuttapong, additional, Swaby, Ramona F., additional, Wei, Bo, additional, Webber, Andrea, additional, Kang, John, additional, Gumuscu, Burak, additional, Yuan, Jianda, additional, and Siu, Lillian, additional

Published
2023
Full Text
View/download PDF

37. A Phase 2 Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Author

Hanna, Glenn J., primary, Ahn, Myung-Ju, additional, Muzaffar, Jameel, additional, Keam, Bhumsuk, additional, Bowles, Daniel W., additional, Wong, Deborah J., additional, Ho, Alan L., additional, Kim, Sung-Bae, additional, Worden, Francis, additional, Yun, Tak, additional, Meng, Xianzhang, additional, Van Tornout, Jan M., additional, Conlan, Maureen G., additional, and Kang, Hyunseok, additional

Published
2023
Full Text
View/download PDF

38. Abstract CT077: Association of tumor mutational burden (TMB) and clinical outcomes with tislelizumab versus chemotherapy in esophageal cell carcinoma (ESCC) from RATIONALE-302

Author

Shen, Lin, primary, Shu, Yongqian, additional, Zhao, Kuaile, additional, Satoh, Taroh, additional, Chen, Zhendong, additional, Van Cutsem, Eric, additional, Yu, Guohua, additional, Wu, Jun, additional, Hsu, Chih-Hung, additional, Kim, Sung Bae, additional, Du, Wenting, additional, Shi, Yang, additional, Huang, Ruiqi, additional, Li, Qiao, additional, Shi, Jingwen, additional, Zhang, Yun, additional, and Ken, Kato, additional

Published
2023
Full Text
View/download PDF

39. Supplementary Data from Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Author

Jerusalem, Guy, primary, Park, Yeon Hee, primary, Yamashita, Toshinari, primary, Hurvitz, Sara A., primary, Modi, Shanu, primary, Andre, Fabrice, primary, Krop, Ian E., primary, Gonzàlez Farré, Xavier, primary, You, Benoit, primary, Saura, Cristina, primary, Kim, Sung-Bae, primary, Osborne, Cynthia R., primary, Murthy, Rashmi K., primary, Gianni, Lorenzo, primary, Takano, Toshimi, primary, Liu, Yali, primary, Cathcart, Jillian, primary, Lee, Caleb, primary, and Perrin, Christophe, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Data from Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Author

Jerusalem, Guy, primary, Park, Yeon Hee, primary, Yamashita, Toshinari, primary, Hurvitz, Sara A., primary, Modi, Shanu, primary, Andre, Fabrice, primary, Krop, Ian E., primary, Gonzàlez Farré, Xavier, primary, You, Benoit, primary, Saura, Cristina, primary, Kim, Sung-Bae, primary, Osborne, Cynthia R., primary, Murthy, Rashmi K., primary, Gianni, Lorenzo, primary, Takano, Toshimi, primary, Liu, Yali, primary, Cathcart, Jillian, primary, Lee, Caleb, primary, and Perrin, Christophe, primary

Published
2023
Full Text
View/download PDF

41. Data from Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Author

Jerusalem, Guy, primary, Park, Yeon Hee, primary, Yamashita, Toshinari, primary, Hurvitz, Sara A., primary, Modi, Shanu, primary, Andre, Fabrice, primary, Krop, Ian E., primary, Gonzàlez Farré, Xavier, primary, You, Benoit, primary, Saura, Cristina, primary, Kim, Sung-Bae, primary, Osborne, Cynthia R., primary, Murthy, Rashmi K., primary, Gianni, Lorenzo, primary, Takano, Toshimi, primary, Liu, Yali, primary, Cathcart, Jillian, primary, Lee, Caleb, primary, and Perrin, Christophe, primary

Published
2023
Full Text
View/download PDF

42. Data from Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Author

Jerusalem, Guy, primary, Park, Yeon Hee, primary, Yamashita, Toshinari, primary, Hurvitz, Sara A., primary, Modi, Shanu, primary, Andre, Fabrice, primary, Krop, Ian E., primary, Gonzàlez Farré, Xavier, primary, You, Benoit, primary, Saura, Cristina, primary, Kim, Sung-Bae, primary, Osborne, Cynthia R., primary, Murthy, Rashmi K., primary, Gianni, Lorenzo, primary, Takano, Toshimi, primary, Liu, Yali, primary, Cathcart, Jillian, primary, Lee, Caleb, primary, and Perrin, Christophe, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Data from Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Author

Jerusalem, Guy, primary, Park, Yeon Hee, primary, Yamashita, Toshinari, primary, Hurvitz, Sara A., primary, Modi, Shanu, primary, Andre, Fabrice, primary, Krop, Ian E., primary, Gonzàlez Farré, Xavier, primary, You, Benoit, primary, Saura, Cristina, primary, Kim, Sung-Bae, primary, Osborne, Cynthia R., primary, Murthy, Rashmi K., primary, Gianni, Lorenzo, primary, Takano, Toshimi, primary, Liu, Yali, primary, Cathcart, Jillian, primary, Lee, Caleb, primary, and Perrin, Christophe, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Data from Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Author

Jerusalem, Guy, primary, Park, Yeon Hee, primary, Yamashita, Toshinari, primary, Hurvitz, Sara A., primary, Modi, Shanu, primary, Andre, Fabrice, primary, Krop, Ian E., primary, Gonzàlez Farré, Xavier, primary, You, Benoit, primary, Saura, Cristina, primary, Kim, Sung-Bae, primary, Osborne, Cynthia R., primary, Murthy, Rashmi K., primary, Gianni, Lorenzo, primary, Takano, Toshimi, primary, Liu, Yali, primary, Cathcart, Jillian, primary, Lee, Caleb, primary, and Perrin, Christophe, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Methods and Materials, Figures S1-S3, Tables S1-S5 from Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck

Author

Kim, Han Sang, primary, Kwon, Hyeong Ju, primary, Jung, Inkyung, primary, Yun, Mi Ran, primary, Ahn, Myung-Ju, primary, Kang, Byung Woog, primary, Sun, Jong-Mu, primary, Kim, Sung Bae, primary, Yoon, Dok-Hyun, primary, Park, Keon Uk, primary, Lee, Se-Hoon, primary, Koh, Yoon Woo, primary, Kim, Se Hun, primary, Choi, Eun Chang, primary, Koo, Dong Hoe, primary, Sohn, Jin Hee, primary, Kim, Bomi, primary, Kwon, Nak-Jung, primary, Yun, Hwan Jung, primary, Lee, Min Goo, primary, Lee, Ji Hyun, primary, Kim, Tae-Min, primary, Kim, Hye Ryun, primary, Kim, Joo Hang, primary, Paik, Soonmyung, primary, and Cho, Byoung Chul, primary

Published
2023
Full Text
View/download PDF

46. Figure S2 from Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

Author

Vathiotis, Ioannis A., primary, Moutafi, Myrto K., primary, Divakar, Prajan, primary, Aung, Thazin Nwe, primary, Qing, Tao, primary, Fernandez, Aileen, primary, Yaghoobi, Vesal, primary, El-Abed, Sarra, primary, Wang, Yingbo, primary, Guillaume, Sebastien, primary, Nuciforo, Paolo, primary, Huober, Jens, primary, Di Cosimo, Serena, primary, Kim, Sung-Bae, primary, Harbeck, Nadia, primary, Gomez, Henry, primary, Shafi, Saba, primary, Syrigos, Konstantinos N., primary, Fountzilas, George, primary, Sotiriou, Christos, primary, Pusztai, Lajos, primary, Warren, Sarah, primary, and Rimm, David L., primary

Published
2023
Full Text
View/download PDF

47. Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Author

Kuemmel, Sherko, primary, Campone, Mario, primary, Loirat, Delphine, primary, Lopez, Rafael Lopez, primary, Beck, J. Thaddeus, primary, De Laurentiis, Michelino, primary, Im, Seock-Ah, primary, Kim, Sung-Bae, primary, Kwong, Ava, primary, Steger, Guenther G., primary, Adelantado, Esther Zamora, primary, Duhoux, Francois P., primary, Greil, Richard, primary, Kuter, Irene, primary, Lu, Yen-Shen, primary, Tibau, Ariadna, primary, Özgüroğlu, Mustafa, primary, Scholz, Christian W., primary, Singer, Christian F., primary, Vega, Estela, primary, Wimberger, Pauline, primary, Zamagni, Claudio, primary, Couillebault, Xuan-Mai, primary, Fan, Liqiong, primary, Guerreiro, Nelson, primary, Mataraza, Jennifer, primary, Sand-Dejmek, Janna, primary, and Chan, Arlene, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Author

Kuemmel, Sherko, primary, Campone, Mario, primary, Loirat, Delphine, primary, Lopez, Rafael Lopez, primary, Beck, J. Thaddeus, primary, De Laurentiis, Michelino, primary, Im, Seock-Ah, primary, Kim, Sung-Bae, primary, Kwong, Ava, primary, Steger, Guenther G., primary, Adelantado, Esther Zamora, primary, Duhoux, Francois P., primary, Greil, Richard, primary, Kuter, Irene, primary, Lu, Yen-Shen, primary, Tibau, Ariadna, primary, Özgüroğlu, Mustafa, primary, Scholz, Christian W., primary, Singer, Christian F., primary, Vega, Estela, primary, Wimberger, Pauline, primary, Zamagni, Claudio, primary, Couillebault, Xuan-Mai, primary, Fan, Liqiong, primary, Guerreiro, Nelson, primary, Mataraza, Jennifer, primary, Sand-Dejmek, Janna, primary, and Chan, Arlene, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Author

Kuemmel, Sherko, primary, Campone, Mario, primary, Loirat, Delphine, primary, Lopez, Rafael Lopez, primary, Beck, J. Thaddeus, primary, De Laurentiis, Michelino, primary, Im, Seock-Ah, primary, Kim, Sung-Bae, primary, Kwong, Ava, primary, Steger, Guenther G., primary, Adelantado, Esther Zamora, primary, Duhoux, Francois P., primary, Greil, Richard, primary, Kuter, Irene, primary, Lu, Yen-Shen, primary, Tibau, Ariadna, primary, Özgüroğlu, Mustafa, primary, Scholz, Christian W., primary, Singer, Christian F., primary, Vega, Estela, primary, Wimberger, Pauline, primary, Zamagni, Claudio, primary, Couillebault, Xuan-Mai, primary, Fan, Liqiong, primary, Guerreiro, Nelson, primary, Mataraza, Jennifer, primary, Sand-Dejmek, Janna, primary, and Chan, Arlene, primary

Published
2023
Full Text
View/download PDF

50. Abstract P4-01-15: Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)

Author

Miller, Kathy, primary, Tolaney, Sara, additional, Emens, Leisha A., additional, Kim, Sung-Bae, additional, Hamilton, Erika, additional, Saura, Cristina, additional, Sanz, Lucia, additional, Boni, Valentina, additional, Lynce, Filipa, additional, Cejalvo, Juan Miguel, additional, Crozier, Jennifer, additional, Wang, Shirley, additional, Uppal, Hirdesh, additional, Hannah, Alison L., additional, and Hurvitz, Sara, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results